Literature DB >> 19783665

Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth.

Michael R Douglas1, Kevin C Morrison, Steven J Jacques, Wendy E Leadbeater, Ana Maria Gonzalez, Martin Berry, Ann Logan, Zubair Ahmed.   

Abstract

Inhibition of central nervous system axon growth is reportedly mediated in part by calcium-dependent phosphorylation of axonal epidermal growth factor receptor, with local administration of the epidermal growth factor receptor kinase inhibitors AG1478 and PD168393 to an optic nerve lesion site promoting adult retinal ganglion cell axon regeneration. Here, we show that epidermal growth factor receptor was neither constitutively expressed, nor activated in optic nerve axons in our non-regenerating and regenerating optic nerve injury models, a finding that is inconsistent with phosphorylated epidermal growth factor receptor-dependent intra-axonal signalling of central nervous system myelin-related axon growth inhibitory ligands. However, epidermal growth factor receptor was localized and activated within most glia in the retina and optic nerve post-injury, and thus an indirect glial-dependent mechanism for stimulated retinal ganglion cell axon growth by epidermal growth factor receptor inhibitors seemed plausible. Using primary retinal cultures with added central nervous system myelin extracts, we confirmed previous reports that AG1478/PD168393 blocks epidermal growth factor receptor activation and promotes disinhibited neurite outgrowth. Paradoxically, neurites did not grow in central nervous system myelin extract-containing cultures after short interfering ribonucleic acid-mediated knockdown of epidermal growth factor receptor. However, addition of AG1478 restored neurite outgrowth to short interfering ribonucleic acid-treated cultures, implying that epidermal growth factor receptor does not mediate AG1478-dependent effects. TrkA-/B-/C-Fc fusion proteins and the kinase blocker K252a abrogated the neuritogenic activity in these cultures, correlating with the presence of the neurotrophins brain derived neurotrophic factor, nerve growth factor and neurotrophin-3 in the supernatant and increased intracellular cyclic adenosine monophosphate activity. Neurotrophins released by AG1478 stimulated disinhibited retinal ganglion cell axon growth in central nervous system myelin-treated cultures by the induction of regulated intramembraneous proteolysis of p75(NTR) and Rho inactivation. Retinal astrocytes/Müller cells and retinal ganglion cells were the source of neurotrophins, with neurite outgrowth halved in the presence of glial inhibitors. We attribute AG1478-stimulated neuritogenesis to the induced release of neurotrophins together with raised cyclic adenosine monophosphate levels in treated cultures, leading to axon growth and disinhibition by neurotrophin-induced regulated intramembraneous proteolysis of p75(NTR). These off-target effects of epidermal growth factor receptor kinase inhibition suggest a novel therapeutic approach for designing treatments to promote central nervous system axon regeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783665     DOI: 10.1093/brain/awp240

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

Review 1.  New Insights into the Roles of Nogo-A in CNS Biology and Diseases.

Authors:  Yun-Peng Sui; Xiao-Xi Zhang; Jun-Lin Lu; Feng Sui
Journal:  Neurochem Res       Date:  2015-08-13       Impact factor: 3.996

2.  Transforming growth factor α transforms astrocytes to a growth-supportive phenotype after spinal cord injury.

Authors:  Robin E White; Meghan Rao; John C Gensel; Dana M McTigue; Brian K Kaspar; Lyn B Jakeman
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

3.  Combined suppression of CASP2 and CASP6 protects retinal ganglion cells from apoptosis and promotes axon regeneration through CNTF-mediated JAK/STAT signalling.

Authors:  Vasanthy Vigneswara; Nsikan Akpan; Martin Berry; Ann Logan; Carol M Troy; Zubair Ahmed
Journal:  Brain       Date:  2014-04-10       Impact factor: 13.501

4.  Human Cytomegalovirus Requires Epidermal Growth Factor Receptor Signaling To Enter and Initiate the Early Steps in the Establishment of Latency in CD34+ Human Progenitor Cells.

Authors:  Jung Heon Kim; Donna Collins-McMillen; Jason C Buehler; Felicia D Goodrum; Andrew D Yurochko
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery.

Authors:  Rebecca Robinson; Stephen R Viviano; Jason M Criscione; Cicely A Williams; Lin Jun; James C Tsai; Erin B Lavik
Journal:  ACS Nano       Date:  2011-06-09       Impact factor: 15.881

6.  DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist.

Authors:  Vidhya Ramaswamy; Adam Monsalve; Larysa Sautina; Mark S Segal; Jon Dobson; Josephine B Allen
Journal:  Nucleic Acid Ther       Date:  2015-06-30       Impact factor: 5.486

7.  Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage.

Authors:  Hai-Bo Tan; Yi-Sheng Zhong; Yu Cheng; Xi Shen
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

8.  Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.

Authors:  E Merit Reyes-Reyes; Francesca R Šalipur; Mitra Shams; Matthew K Forsthoefel; Paula J Bates
Journal:  Mol Oncol       Date:  2015-04-09       Impact factor: 6.603

9.  Attenuating the DNA damage response to double-strand breaks restores function in models of CNS neurodegeneration.

Authors:  Richard I Tuxworth; Matthew J Taylor; Ane Martin Anduaga; Alaa Hussien-Ali; Sotiroula Chatzimatthaiou; Joanne Longland; Adam M Thompson; Sharif Almutiri; Pavlos Alifragis; Charalambos P Kyriacou; Boris Kysela; Zubair Ahmed
Journal:  Brain Commun       Date:  2019-07-02

10.  Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury.

Authors:  Vasanthy Vigneswara; Martin Berry; Ann Logan; Zubair Ahmed
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.